One of the most pressing problems of modern parasitology, that remains unresolved as yet, is how to conduct a rational therapy when treating cutaneous leishmaniosis.
The disease can be met in several regions of Tajikistan, Turkmenistan, Uzbekistan and Trans-Caucasus and is widely spread in the countries of Africa and Asia. The outbreaks of cutaneous leishmaniosis usually occur from August to November. The disease’s seasonal character is linked to biology of its carriers – mosquito fleet, which inhabit the burrows of rodents, whose number, in turn, increases dramatically in oases and irrigated deserts in this very period.
Leishmaniosis is an endemic disease in almost 100 countries worldwide, where, according to WHO data, more than 350 million people are exposed to risk of infection. A growing incidence of the disease is facilitated, to a considerable extent, by the spread of poverty, while its therapy remains very expensive. At the same time, resistance of the leishmaniosis disease carrier to applicable medicines tends to increase.
In 2008, the Samarkand Institute of Medical Parasitology named after L. Isaev carried out scientific-experimental research into the influence of the preparation FarGALS on the growth and reproduction of Leishmania major, a carrier of zoonotic cutaneous leishmaniosis in vitro, which showed that on the 6th day of growth in the culture, with concentration of 0.1 per cent, the preparation FarGALS slows down the growth in the number of parasites, while in cases where its concentration was 1 per cent and over, the destruction of parasites was recorded to take place in one hour already. This fact served as the ground for pressing ahead with further investigation of the preparation FarGALS when treating cutaneous leishmaniosis in people.
Clinical trials of the preparation FarGALS were performed on the basis of the Surkhandarya Province Dermato-Venerologic Clinic. Their results showed that when applying the preparation FarGALS, the discharge of seropurulent liquid terminated in 4-6 days, papillae tore away in 10-12 days, an ulcer’s bottom was covered with fresh epithelium in 20-25 days and the secondary cicatrix formed in 28-30 days.
The following conclusions were inferred in the course of the clinical trials under discussion: the preparation FarGALS has a strongly pronounced antimicrobial effect on the growth and reproduction of Leishmania major, the disease carrier of zoonotic cutaneous leishmaniosis, while enjoying a marked necrotic and anti-inflammatory effect on tissues.
The preparation FarGALS has a wound-healing activity. Comparison of results by the wound cicatrization term showed that in patients with cutaneous leishmaniosis in the acute necrotizing form, who were treated with the preparation FarGALS, cicatrization and scarring of wounds took place 120-150 days earlier than in patients under conventional therapy.
Preparation prescription scheme: FarGALS is used locally in the form of applications diluted with distilled water 1:1 twice a day, within 10-20 days. FarGALS is notably efficient at the “eminence” stage.